3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
8
Other hematologic neoplasm
5
Plasma cell
4
Thoracic
3
Gastrointestinal
3
Tumor-Agnostic
1
Myeloid
1
Gynecologic
1
Conditions
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
143
fludarabine phosphate
130
Busulfan
109
Tacrolimus
94
fludarabine
93
Mycophenolic Acid
90
Whole-Body Irradiation
84
Peripheral Blood Stem Cell Transplantation
81
Imatinib Mesylate
69
Antilymphocyte Serum
67
Cyclosporine
66
Azacitidine
64
Cytarabine
63
Methotrexate
60
Melphalan
60
Filgrastim
50
Granulocyte Colony-Stimulating Factor
40
Decitabine
40
Thiotepa
38
thymoglobulin
34
Stem Cell Transplantation
34
Dasatinib
34
Radiotherapy
33
nilotinib
31
ruxolitinib
28
Cord Blood Stem Cell Transplantation
28
venetoclax
26
Clofarabine
25
Specimen Handling
24
Methylprednisolone
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Maintenance
×
Myeloid
×
Clear all
NCT07572929
2026-05-07
PREeMPT
Medical College of Wisconsin
Phase 2
Not yet recruiting
450 enrolled